Join us for an insightful presentation by Duy Trieu, CTO of Nanyang Biologics, at the Genesis Final Round during SuperAI Singapore 2025. This talk unveils the cutting-edge advancements in AI-driven drug discovery being pioneered by Nanyang Biologics. The company's proprietary AI model, DTIGN, revolutionizes the understanding of chemical compound interactions within the human body. By analyzing 3D structures and predicting bioactivity with 27% greater accuracy than traditional methods, DTIGN accelerates pharmaceutical development and enables precise results for FGMA and consumer health companies.

​

Duy highlights the strategic creation of a vast natural compound library, housing over 10 million unique compounds derived from plants. This resource, compiled through advanced LLM-based data processing from over 20 million scientific papers, responds to the growing demand for science-backed, nature-derived products. Nanyang Biologics collaborates with global partners such as Nvidia, Equinix, and HPE, integrating their AI technology into broader ecosystems and enhancing the market reach of their partners.

​

Discover how Nanyang Biologics is setting new benchmarks in the pharmaceutical landscape, planning expansion into the US market, and preparing significant collaborations with industry giants. Learn about their innovative approaches to data authenticity, proprietary IP handling, and agile go-to-market strategies that leverage the synergy between AI and the drug development industry.

​

For those interested in the intersection of AI and biopharma, this talk offers crucial insights and a glimpse into the future direction of drug discovery. Like, comment, and subscribe to stay updated with the latest innovations and leadership discussions from SuperAI Singapore 2025.